



Date: 22-10-2024

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex,
Bandra East, Mumbai-400051
Scrip Code: MUKKA

BSE Limited
Listing Department
Dalal Street,
Mumbai-400001
Scrip Code: 544135

Dear Sir/Madam,

Subject: Newspaper Advertisement - Notice of 01/2024 Extra-Ordinary General Meeting and e-voting.

Pursuant to Regulation 30 read with Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in compliance with various circulars issued by the Ministry of Corporate Affairs, we hereby enclose copies of newspaper advertisement published today i.e. Tuesday, 22nd October 2024, in **Business Standard** (English) and **Vijaya Karnataka** (Kannada) in respect of information regarding the 01/2024 Extra-Ordinary General Meeting of the Company scheduled to be held on Saturday, 16th day of November 2024 at 03:00 P.M (IST) through Video Conferencing (VC)/Other Audio-Visual Means (OAVM) and information relating to e-voting.

This is for your information and records.

Thank you,

For **Mukka Proteins Limited**

Mehaboobsab Mahmadgous Chalyal
Company Secretary & Compliance Officer

Encl: as above.

Mfrs. & Exporters of Steam Dried Fish Meal, Fish Oil & Fish Soluble Paste

Factory : D. No. 14-161 to 164, Sasihithlu Road, Mukka, Mangaluru - 575021. Karnataka, India


Office : Mukka Corporate House, Door No. 18-2-16/4, First Cross, NG Road, Attavara, Mangaluru, Dakshina Kannada, Karnataka, India - 575001

☎ : (O) +91 824 2420772, 2442889, 4252889 | Fax : +91 824 2426405

E-mail : info@mukkaproteins.com - Website : www.mukkaproteins.com - CIN : L05004KA2010PLC055771

DSP
ASSET MANAGERS

50 Years of Insight

		SOLARA ACTIVE PHARMA SCIENCES LIMITED CIN: L24230MH2017PLC291636 Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703. Address: 2nd Floor, Admin Block 27, Vandaloor kelambakkam Road, Keelakottaiyur Village, Chennai 600 127.					
EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2024 (Rs. in Crores except per share data)							
Sl. No.	Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for the current period ended	Year to date figures for the previous period ended	Previous Financial Year ended
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
	Continuing operations:						
1	Total income from operations	346.95	363.49	425.24	710.44	777.55	1,288.92
2	Net Profit for the period before tax (before exceptional items)	8.01	(13.46)	(11.84)	(5.45)	(41.20)	(298.25)
3	Net Profit for the period before tax (after exceptional items)	8.01	(13.46)	(17.06)	(5.45)	(46.42)	(488.42)
4	Net Profit for the period after tax	8.01	(13.46)	(17.06)	(5.45)	(36.17)	(566.96)
5	Other Comprehensive Income for the period	1.68	(0.01)	0.23	1.67	0.23	0.49
6	Total Comprehensive Income for the period (4 + 5)	9.69	(13.47)	(16.83)	(3.78)	(35.94)	(566.47)
7	Equity Share Capital	40.21	40.21	36.00	40.21	36.00	36.00
8	Other Equity						897.91
9	Earnings Per Share (of Rs. 10/- each) (for continuing operations) -						
	Basic (Rs.)	2.54	(3.50)	(4.47)	(0.96)	(9.47)	(148.27)
	Diluted (Rs.)	2.54	(3.50)	(4.47)	(0.96)	(9.47)	(148.27)

Notes:

- The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the websites of the NSE Limited (www.nseindia.com), BSE Limited (www.bseindia.com) and at the Company's website (www.solara.co.in)
- The above consolidated financial results of Solara Active Pharma Sciences Limited ("the Parent" or the Company") and its subsidiaries (together referred to as "the group") as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on October 21, 2024. The results for the quarter and six months ended September 30, 2024 has been reviewed by Deloitte Haskins & Sells LLP, the statutory auditors of the Company. The statutory auditors of the Company have expressed an unmodified conclusion in respect of limited review for the quarter and six months ended September 30, 2024.
- The Parent, vide its letter of offer dated May 09, 2024 offered upto 1,19,98,755 Equity shares of face value of Rs.10/- each at a price of Rs. 375/- per Equity share (including Share premium of Rs. 365/- per Equity share) for an amount aggregating Rs. 449.95 crores to the existing share holders of the Parent on right basis in the ratio of One Equity share for every three Equity shares held by the Equity shareholders on the record date i.e May 15, 2024. Rights issue has been done in accordance with Section 62(1)(a) of the Companies Act,2013 and other applicable laws. The Parent has allotted 1,19,98,755 Nos. of partly paid up equity shares on 19 June, 2024.
Accordingly, the paid-up equity share capital of the Company has increased from Rs. 36,00,52,670/- divided into 3,60,05,267 fully paid up Equity Shares of face value of Rs.10 each to Rs.40,20,48,313/- divided into 3,60,05,267 fully paid up Equity Shares of face value of Rs.10/- each and 1,19,98,755 partly paid up Equity Shares having face value of Rs. 10 each with the Paid up value of Rs. 3.50/- per Share. Pursuant to the Rights issue, earnings per share (EPS) in respect of previous year / periods have been adjusted as per Indian Accounting Standard 33 "Earnings per share", prescribed under Section 133 of the Companies Act, 2013.

For and on behalf of board

Place : Bengaluru
Date : October 21, 2024

Poorvank Purohit - MD & CEO
DIN: 10158900

RNI No. KARKAN/2001/5072